Conditions: Acute Myeloid Leukemia
Keywords: Acute Myeloid Leukemia AML Decitabine Dacogen MGI PHARMA, INC.
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 55
Healthy volunteers: no

Brief summary:
The purpose of this study is to estimate the rate of complete remission, as well as overall survival, in older patients with Acute Myeloid Leukemia (AML).

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Decitabine
Intervention descriptions: intervention 1: 20 mg/m\^2, IV on days 1-5 of each 28 day cycle; until death, progression or unacceptable toxicity develops.

Protocol document: